Trinity Biotech Q4 net loss widens to $17.5 million; revenue falls to $11.1 million

• Trinity Biotech posted Q4 2025 revenue of USD 11.1 million, down 30.19% year on year, while net loss widened to USD 17.5 million.
• Gross margin rose 4.4 percentage points to 35.2%, while adjusted EBITDA improved to negative USD 0.5 million.
• For 2025, revenue fell to USD 43.8 million, while net loss widened to USD 37.4 million, including a one-off IFRS-driven charge of USD 10 million tied to modification of Perceptive financing arrangements in December 2025.
• Gross margin increased 3.8 percentage points to 38.6%, while adjusted EBITDA improved to negative USD 5.9 million.
• Company named Jerry Lydon head of North America commercial operations, highlighting scaled TrinScreen HIV outsourced manufacturing to targeted production levels by early Q2 2026 and start of Uni-Gold HIV outsourced manufacturing scale-up in Q2 2026 following early-2026 regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-000915), on May 06, 2026, and is solely responsible for the information contained therein.